1. Overview
  2. BHF · Bio-Engineered Hair Follicle
BHF · SECTION ROOTSubsystems: 8

Bio-Engineered Hair Follicle

Autologous, co-cultured engineered follicle on a gradient-stiffness PLGA/PCL micro-scaffold embedded in crosslinked hyaluronan hydrogel with VEGF/PDGF-loaded sustained-release microspheres.

BHF · Cellular biology, scaffold design & integrationFIG BHF.0
Cross-section of the engineered hair follicle showing scaffold and cellular layers
FIG · BLUEPRINT
DARK · 16:9
Subsystem IndexBHF-IDX
BHF-01 · REV C.0
Bulge Epithelial Stem Cells

CD200⁺ / K15⁺ / K19⁺ epithelial stem cells isolated by FACS from autologous occipital donor follicles, expanded under defined KSFM conditions.

BHF-02 · REV C.2
Dermal Papilla Cells & Inductive Signaling

Dermal papilla cells expanded as 3D spheroids to preserve inductive signature (ALP⁺, versican⁺, corin⁺) and rescue hair-inductive capacity lost in 2D.

BHF-03 · REV B.4
Epithelial–Mesenchymal Co-culture

Layered co-culture aggregates eHFSCs with DP spheroids in a defined cocktail (CHIR99021, LDN-193189, FGF7) that recapitulates the Wnt↑/BMP↓/FGF↗ induction window.

BHF-04 · REV B.1
Crosslinked Hyaluronan Hydrogel ECM

Thiol-ene crosslinked methacrylated hyaluronic acid hydrogel with storage modulus G′ ≈ 1.2 kPa, controlled enzymatic degradation, and tunable RGD presentation.

BHF-05 · REV D.0
PLGA/PCL Micro-scaffold with Gradient Stiffness

3D-melt-printed PLGA 75:25 / PCL biphasic micro-scaffold with 50–150 µm interconnected pores and an apico-basal stiffness gradient mirroring the native follicular niche.

BHF-06 · REV B.0
Angiogenic & Immunomodulatory Cargo

PLGA microspheres encapsulating VEGF-165, PDGF-BB, TGF-β3 and IL-10 with engineered burst + sustained release over 21 days.

BHF-07 · REV B.3
Implantation, Vascularization & Maturation Timeline

Day 0–28 integration: implant → capillary sprouting (D3–7) → anastomosis (D10–14) → perfusion (D14–21) → follicular maturation and shaft eruption (D28+).

BHF-08 · REV A.5
Immune Compatibility & Biocompatibility

Autologous cellular fraction (low rejection risk) combined with ISO 10993 biocompatibility-qualified materials and an IL-10/TGF-β3 tolerogenic micro-niche.